- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05162066
BCX9930 para el tratamiento de C3G, IgAN y PMN (RENEW) (RENEW)
Un estudio abierto, de seguridad, tolerabilidad y prueba de concepto de la terapia oral con BCX9930 en sujetos con C3G, IgAN o PMN
The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Barcelona, España
- Investigative Site #1
-
Barcelona, España
- Investigative Site #2
-
Madrid, España
- Investigative Site #1
-
Madrid, España
- Investigative Site #2
-
-
-
-
-
Poitiers, Francia
- Investigative Site
-
Toulouse, Francia
- Investigative Site
-
-
-
-
-
Bari, Italia
- Investigative Site
-
Bergamo, Italia
- Investigative Site
-
Brescia, Italia
- Investigative Site
-
Turin, Italia
- Investigative Site
-
-
-
-
-
Oxford, Reino Unido
- Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Body weight ≥ 40 kilograms (kg)
- Primary diagnosis of C3G, IgAN, or PMN confirmed by central pathology review
- An estimated glomerular filtration rate (eGFR) ≥ 50 milliter per minute per 1.73 meter square (mL/min/1.73 m^2) (or ≥ 30 mL/min/1.73 m^2 after Data Monitoring Committee [DMC] recommendation)
- Receiving treatment with a stable, maximum recommended or maximum tolerated dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 60 days prior to the Day 1 Visit
- Documentation of current vaccinations against Neisseria meningitidis and Streptococcus pneumoniae or willingness to start vaccination series
Exclusion Criteria:
- Known congenital deficiency of C1s, C1r, C1q, C2, or C4
- History of hematopoietic cell transplant or solid organ transplant or anticipated candidate for transplantation
- Myocardial infarction or cerebrovascular accident within 30 days prior to screening, or current and uncontrolled clinically significant cardiovascular or cerebrovascular condition
- History of malignancy within 5 years prior to the screening visit
- Active serious bacterial, viral, or fungal infection or any other serious infection within 14 days of screening
- Treatment with any systemic immunosuppressive or immunomodulatory therapy within 90 days OR anti-CD20 antibody therapies (eg, rituximab) within 180 days prior to the screening visit
- Treatment with renin inhibitors (eg, aliskiren) or sodium-glucose-cotransporter 2 (SGLT2) inhibitors within 60 days prior to Day 1
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: C3G cohort
Approximately 14 eligible participants with C3G will be enrolled. |
Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily |
|
Experimental: IgAN cohort
Approximately 14 eligible participants with IgAN will be enrolled. |
Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily |
|
Experimental: PMN cohort
Approximately 14 eligible participants with PMN will be enrolled. |
Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percent Change From Baseline in 24-hour uPCR at Week 12
Periodo de tiempo: Baseline, Week 12
|
Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease. |
Baseline, Week 12
|
|
Percent Change From Baseline in 24-hour uPCR at Week 24
Periodo de tiempo: Baseline, Week 24
|
Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease. |
Baseline, Week 24
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cambio porcentual desde el valor inicial en la excreción de proteínas en orina de 24 horas
Periodo de tiempo: Línea de base, semanas 12, 24,
|
Línea de base, semanas 12, 24,
|
|
|
Change From Baseline in Estimated Glomerular Filtration Rate
Periodo de tiempo: Baseline, Weeks 12, 24
|
eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula for participants ≥ 18 years old and by the bedside Schwartz formula for participants ≤ 18 years old. eGFR was reported in milliliter per minute per 1.73 per square meter (mL/min/1.73m^2). |
Baseline, Weeks 12, 24
|
|
Number of Participants With a Treatment-emergent Adverse Event (TEAE)
Periodo de tiempo: From first dose up to safety follow-up period (Week 28)
|
An Adverse event (AE) was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug. |
From first dose up to safety follow-up period (Week 28)
|
|
Number of Participants Who Discontinued Due to a TEAE
Periodo de tiempo: From first dose up to safety follow-up period (Week 28)
|
An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug. |
From first dose up to safety follow-up period (Week 28)
|
|
Number of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE)
Periodo de tiempo: From first dose up to safety follow-up period (Week 28)
|
An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug. A serious adverse event (SAE) was an adverse event/reaction that results in any of the following outcomes:
|
From first dose up to safety follow-up period (Week 28)
|
|
Number of Participants Who Experienced a Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 TEAE
Periodo de tiempo: From first dose up to safety follow-up period (Week 28)
|
An AE was any untoward medical occurrence has no causal relationship with the study drug or with the clinical study itself. It was an unfavorable & unintended sign, symptom, syndrome, or illness that developed or worsened during clinical study. TEAEs: AEs that started on or after first dose of treatment through 30 days after the last dose of study drug. All AEs were graded using the CTCAE Grades 1 through 5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL Grade 4: Life-threatening consequences; urgent intervention indicated Grade 5: Death Participants with Grades 3 or 4 AEs were reported |
From first dose up to safety follow-up period (Week 28)
|
|
Number of Participants Who Experienced a CTCAE Treatment-emergent Grade 3 or 4 Laboratory Abnormality
Periodo de tiempo: From first dose up to safety follow-up period (Week 28)
|
Treatment-emergent Laboratory Abnormality were defined as an event that started on or after the first dose of study treatment through 30 days after the last dose of study drug. CTCAE Grades for laboratory abnormalities include: Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death Participants with Grades 3 or 4 laboratory abnormality were reported. |
From first dose up to safety follow-up period (Week 28)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Carla M Nester, MD, MSA, FASN, University of Iowa Stead Family Children's Hospital
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Glomerulonefritis
- Nefritis
- Glomerulonefritis, IGA
- Glomerulonefritis Membranosa
- Glomerulonefritis Membranoproliferativa
Otros números de identificación del estudio
- BCX9930-211
- 2020-005855-19 (Número EudraCT)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .